Free Trial
NASDAQ:ETON

Eton Pharmaceuticals Q1 2025 Earnings Report

Eton Pharmaceuticals logo
$16.97 -0.37 (-2.13%)
Closing price 05/5/2025 04:00 PM Eastern
Extended Trading
$16.98 +0.01 (+0.03%)
As of 05/5/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eton Pharmaceuticals EPS Results

Actual EPS
N/A
Consensus EPS
$0.05
Beat/Miss
N/A
One Year Ago EPS
N/A

Eton Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
$14.33 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eton Pharmaceuticals Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Eton Pharmaceuticals Earnings Headlines

Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
B.Riley Financial Remains a Buy on Eton Pharmaceuticals (ETON)
See More Eton Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eton Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eton Pharmaceuticals and other key companies, straight to your email.

About Eton Pharmaceuticals

Eton Pharmaceuticals (NASDAQ:ETON), a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

View Eton Pharmaceuticals Profile

More Earnings Resources from MarketBeat